Wide Ranks

LRMR

Larimar Therapeutics, Inc.

6.64

Top Statistics
Market Cap 423 M Forward PE -4.09 Revenue Growth 0.00 %
Current Ratio 13.10 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.07 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 203 M Total Cash Per Share 3.19 Total Debt 5 M
Total Debt To Equity 2.70 Current Ratio 13.10 Book Value Per Share 3.11
All Measures
Short Ratio 449.00 % Message Board Id finmb_572350487 Shares Short Prior Month 3 M
Return On Equity -0.4450 City Bala Cynwyd Uuid 0bb9528f-7ec3-38bd-aa61-f67b2741ad55
Previous Close 6.18 First Trade Date Epoch Utc 1 B Book Value 3.11
Beta 0.7130 Total Debt 5 M Volume 644392
Price To Book 2.14 Fifty Two Week Low 3.27 Total Cash Per Share 3.19
Shares Short Previous Month Date 1 B Target Median Price 22.00 Max Age 86400
Recommendation Mean 1.18 Sand P52 Week Change 0.3133 Target Mean Price 21.03
Net Income To Common -64773000 Short Percent Of Float 0.0794 Implied Shares Outstanding 63 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 699820
Average Volume10days 699820 Total Cash 203 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0145 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 6.18 Target Low Price 12.36
Gmt Off Set Milliseconds -18000000 Fifty Day Average 7.23 Open 6.26
Free Cashflow -35223376 State PA Dividend Yield 0.00 %
Return On Assets -0.2855 Time Zone Short Name EST Trailing Eps -1.15
Day Low 6.07 Address1 Three Bala Plaza East Shares Outstanding 63 M
Price Hint 2 Target High Price 36.00 Website https://www.larimartx.com
52 Week Change 0.9359 Average Volume 734889 Forward Eps -1.54
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 1256.70 %
Is_sp_500 False Regular Market Day High 6.66 Profit Margins 0.00 %
Debt To Equity 2.70 Fifty Two Week High 13.68 Day High 6.66
Shares Short 3 M Regular Market Open 6.26 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0518
Operating Cashflow -58288000 Currency USD Time Zone Full Name America/New_York
Market Cap 423 M Is_nasdaq_100 False Zip 19004
Quote Type EQUITY Industry Biotechnology Long Name Larimar Therapeutics, Inc.
Regular Market Day Low 6.07 Held Percent Institutions 1.07 Current Price 6.64
Address2 Suite 506 Enterprise To Ebitda -3.07 Financial Currency USD
Current Ratio 13.10 Industry Disp Biotechnology Number Of Analyst Opinions 11
Country United States Float Shares 31 M Two Hundred Day Average 8.10
Enterprise Value 225 M Forward PE -4.09 Regular Market Volume 644392
Ebitda -73437000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.